| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------|---------|-------|-------|-------|-------|-------------|-------| | | | | | | | | | | | | | | | | | | | × × | | × | | × × | × | × | | natera | | | | | × × | | × | | xxxxx | × | | | | | | | | × × | | × | | × × | × | | | | | | | | × × | | × | × | × | X X X | | | | | | | | × × × × | | × × | × × | × × | × × × x x x | | | | | | | | × × | | × | × | × | x | | | | | | | | × × | | × | × | × | x X ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or Other ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------|-------|-------|-----------------|-------|-------|-------| | | | | | | | | | | | | | | | | | × | × | × | × × | | × | | | 8 natera | | | | × | | | X X X X X X | | | | | | | | | × | | | X X X X X X | | | | | | | | | × | | | x x x x | | × | | | | | | | × | | | × × × × | | × | | | | | | | × | | | X X X X X X X X | | | | | | | | | × | | | × × × × × × × × | | | | | | | | | × | | | × × × × × × × × | ...

Natera, Inc. (NASDAQ:NTRA) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager, Oncology Conference Call Participants Tejas Savant - Morgan Stanley Stephanie Yan - Cowen Catherine Schulte - Baird Matt Sykes - Goldman Sachs Puneet Souda - SVB Securities Operator Welcome to Natera???s 2022 First Quarter Financial Results Conference Call. At this time, all participants ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) 13011 McCallen Pass Building A Suit ...

Natera, Inc. (NASDAQ:NTRA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager of Oncology & Transplant Conference Call Participants Tejas Savant - Morgan Stanley Puneet Souda - SVB Leerink Tycho Peterson - JPMorgan Catherine Schulte - Baird Max Masucci - Cowen & Company Mark Massaro - BTIG Dan Leonard - Wells Fargo Alex Nowak - Craig-Hallum Capital Group Kyle ...

8 natera × × × × × × × × × × × × × × × × × × Ⅹ Ｘ × × × × × × × × × × X X X X X X X × × Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Natera, Inc. Investor presentation Fourth Quarter 2021 Earnings Call Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our pro ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 01-0894487 State or Other Juris ...

8 natera Natera, Inc. Investor presentation JPM 2022 Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ × × × × × × × × Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our proposed products and la ...

Financial Performance - Natera processed 407,000 tests in Q3 2021, a 55% increase compared to Q3 2020[5] - Total revenues for Q3 2021 reached $158 million, representing a 61% growth compared to Q3 2020[5] - Product revenues in Q3 2021 amounted to $151 million, a 62% increase compared to Q3 2020[5] - Natera is raising its revenue guidance from $600-$620 million to $615-$625 million, a $100 million increase from the start of the year[5] - Cash and investments stand at $1,023.9 million as of September 30, 2021, compared to $580.5 million as of June 30, 2021, representing a $443.4 million increase[30] Product Development and Validation - Prospera Kidney demonstrates improved sensitivity with the enhanced algorithm, showing overall sensitivity >99% and specificity 87.5%[17] - The Trifecta Study validates Prospera with Quantification, showing an area under the curve of 0.89 using molecular pathology as truth[18] - Prospera Heart transplant assessment test shows an area under the curve of 0.88 with Quantification[22] - Prospera lung test shows an area under the curve of 0.91 for acute rejection vs stable in the VALID study[23] Oncology - Signatera is selected for NRG Oncology's landmark CIRCULATE-US study[5] - Data validates Signatera velocity metric, showing a 43% 3-year overall survival for patients with fast tumor growth type (137% increase/mo) compared to 100% for slow growth type (27% increase/mo)[27]